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Background: The Headache Impact Test (HIT)-6 was developed and has been validated in patients with various
types of headache. The objective of this study was to report the psychometric properties of the HIT-6 among
patients with chronic migraine.
Methods: Data came from two international, multicenter, randomized, double-blind, placebo-controlled clinical trials of
chronic migraine patients (N = 1,384) undergoing prophylaxis therapy. Confirmatory factor analysis and differential item
functioning (DIF) analysis were used to test the latent structure and cross-cultural comparability of the HIT-6. Reliability,
construct validity, and responsiveness were assessed. Two sets of criterion groups were used: (1) 28-day headache
frequency: <10, 10–14, and ≥15 days; (2) sample quartiles of the total cumulative hours of headache: <140, 140 to <280,
280 to <420, and ≥420 hours. Two sets of responsiveness categories were defined as reduction of <30%, 30% to <50%,
or ≥50% in (1) number of headache days and (2) cumulative hours of headache.
Results: Measurement invariance tests supported the stability of the HIT-6 latent structure across studies. DIF analysis
supported cross-cultural comparability. Good reliability was observed across studies (Cronbach’s α: 0.75–0.92; intraclass
correlation coefficient: 0.76–0.80). HIT-6 scores correlated strongly (−0.86 to −0.59) with scores of the Migraine-Specific
Quality-of-Life Questionnaire. Analysis of variance indicated that HIT-6 scores discriminated across both types of
criterion groups (P<0.001), across studies and time points. HIT-6 change scores were significantly higher in magnitude
in groups experiencing greater improvement (P<0.001).
Conclusion: All measurement properties were consistently verified across the two studies, supporting the validity of the
HIT-6 among chronic migraine patients.
Trial registration: NCT00156910 and NCT00168428 on www.ClinicalTrials.gov.
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Migraine is recognized as a major cause of disability, ad-
versely affecting the daily functioning of an estimated
12% of the US population [1,2]. For some patients, the
frequency of migraine attacks increases over time and
progresses to high-frequency episodic migraine (10–14
days per month) or chronic migraine (≥15 days per
month) [3]. Patients with episodic migraine (<15 days
per month) are estimated to transition into chronic mi-
graine at a rate of about 2.5% per year [4]. Increases in
the frequency of headache leading to chronic migraine* Correspondence: rrbaum@qualitymetric.com
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article, unless otherwise stated.are known to be accompanied by anatomical and func-
tional changes [5]. Understanding the impact of these
changes helps define the characteristics of chronic mi-
graine patients and how they differ from those of pa-
tients with lower frequency migraine. Frequency of
headaches is the key distinguishing feature used to clas-
sify migraine subtypes (e.g., low-frequency episodic mi-
graine, high-frequency episodic migraine, and chronic
migraine) [6]; however, researchers have become increas-
ingly aware that the differential impact of migraine can-
not be fully assessed through the exclusive use of such
measures. This has led to the increasing use of disease-
specific patient-reported outcome (PRO) measures in
migraine research and clinical practice [7]. The use of
standardized PRO instruments has contributed greatlyentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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order on patients’ health-related quality of life (HRQOL),
and these measures are currently recommended by ex-
perts in the field [8,9]. Nevertheless, the integrity of PRO-
based evaluations rests on the availability of psychometric
data endorsing its validity among the clinical population
of interest. Several disease-specific measures of quality of
life were developed and validated in samples of patients
with headache. PRO instruments measuring headache im-
pact are often used across different migraine subtypes, the
assumption being that the instrument’s validity is retained
across these clinical subgroups. However, evidence of an
instrument’s properties among specific subtypes of mi-
graine is often not available.
The 6-item Headache Impact Test (HIT-6™) is a brief
tool for assessing the impact of headache in both clinical
research and practice. The development and validation
study indicated that the HIT-6 possessed good psycho-
metric properties among headache sufferers [10]. Another
study conducted among patients seeking headache-specialty
care confirmed high indices of reliability, as well as construct
and face validity [11]. Several important properties of the
HIT-6 have been documented, including its between-group
and within-group minimally important difference (MID)
[12,13] and its ability to detect change in clinical measures
of migraine patients [14]. Although strong evidence has
been found supporting the validity of the HIT-6 in headache
sufferers in general, a full evaluation of the HIT-6 psycho-
metric properties specifically in a subgroup of headache
patients with chronic migraine, a distinct headache
disorder characterized by the International Classification
of Headache Disorders Revised Criteria (ICHD-IIR)
as ≥15 headache days per month for at least 3 months,
with ≥8 days per month fulfilling criteria for migraine
without aura, has not been conducted. The ability to de-
tect significant change in clinical parameters [14,15] has
been evaluated in samples of patients with chronic daily
headache or chronic migraine, but a full psychometric
evaluation, including longitudinal measurement invariance
and differential item functioning, was not performed. Fur-
thermore, none of the previous validation studies [10,11]
were conducted using clinical trial samples. This is an im-
portant aspect of validity because PRO instruments are
key elements in efficacy studies of migraine treatment.
The current study used data from two independent clin-
ical trials of chronic migraine patients to comprehensively




Data used in the analyses came from a total sample of
1,384 patients with chronic migraine who participated in
2 studies that evaluated onabotulinumtoxinA (BOTOX®,Allergan, Inc.) as headache prophylaxis – the Phase III
REsearch Evaluating Migraine Prophylaxis Therapy with
Botulinum Toxin Type A (PREEMPT) trials [16,17].
Both PREEMPT trials were multicenter, double-blind,
randomized, and placebo-controlled. The total study
period consisted of 60 weeks, which included a 4-week
baseline phase capturing inclusion/exclusion informa-
tion, followed by a 24-week double-blind treatment
phase, and a final 32-week, open-label extension phase.
The studies were conducted between January of 2006
and August of 2008 in the United States, Canada, the
United Kingdom, Croatia, Germany and Switzerland.
To be considered eligible for the trial, participants had
to be between the ages of 18 and 65 years and fulfill
each of the following headache-related criteria: 1) history
of migraine headache disorder meeting any of the diag-
nostic criteria listed in ICHD-II [18] section 1, for mi-
graine, with the exception of “complicated migraine”;
2) ≥4 distinct headache episodes each with a duration of
at least 4 hours during the 4-week baseline phase; 3) ≥15
headache days during the 4-week baseline phase, with
each headache day consisting of ≥4 hours of continuous
headache; and 4) ≥50% of baseline headache days were
migraine or probable migraine days. Headache-related
exclusion criteria included any of the following criteria:
1) diagnosis of complicated migraine, basilar migraine,
ophthalmoplegic migraine, or migrainous infarction; 2)
use of any headache prophylactic medication within
28 days prior to screening; 3) diagnosis of chronic
tension-type headache, hypnic headache, hemicrania
continua, or new daily persistent headache; 4) headache
attributed to another disorder (e.g., cervical dystonia,
craniotomy, head/neck trauma); and 5) unremitting
headache lasting continuously throughout the 4-week
baseline period. In addition, participants with a Beck De-
pression Inventory score >24 at week 4 baseline period
were also excluded.
Data from the 24-week, double-blinded period of the
two trials were used for the current study. All analyses
were conducted by pooling treatment groups.
Measures
HIT-6
The items of the HIT-6 cover several HRQOL domains:
pain, social functioning, role functioning, vitality, cogni-
tive functioning, and psychological distress. Each item is
answered on a 5-point Likert scale (6 = never, 8 = rarely,
10 = sometimes, 11 = very often, 13 = always). The scor-
ing of the HIT-6 was derived to approximate the total
score obtained from a larger battery of items, using re-
sults from item response theory (IRT) [10]. The final
score is obtained from simple summation of the six
items. The HIT-6 total score ranges between 36 and 78,
with larger scores reflecting greater impact. Four groups
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scores: scores ≤49 represent little or no impact; scores
between 50 and 55 represent some impact; scores be-
tween 56 and 59 represent substantial impact; and
scores ≥60 indicate severe impact [19]. The HIT-6 was
administered to study participants at each office visit
of the double-blind phase: at baseline and every 4 weeks
up to Week 24.
Migraine-specific questionnaire
The Migraine-Specific Quality-of-Life Questionnaire (MSQ)
is a relatively longer questionnaire compared to the HIT-6
and is used to assess the impact of migraine on the HRQOL
of migraine patients [20,21]. In its most current version
(version 2.1), the MSQ is composed of 14 items, each
measured on a 6-point scale (1 = none of the time, 6 =
all of the time), with higher scores reflecting greater
impact. The MSQ measures the impact of migraine on
the patient’s HRQOL in the past 4 weeks across three
dimensions: role function-restrictive (7 items), role
function-preventive (4 items), and emotional function
(3 items). Raw dimension scores are computed as a
sum of item responses and rescaled to a 0–100 scale
with severity direction reversed (higher scores represent
better migraine-specific quality of life). Study participants
were asked to answer the MSQ at baseline, Week 12, and
Week 24.
Migraine diary
Using a self-administered diary, participants were asked to
report information on the timing of headaches, headache-
specific characteristics, symptoms, and use of any acute
headache pain medication. A headache day was defined as
a day with 4 or more continuous hours of headache. A mi-
graine day was defined as a day with 4 or more continuous
hours of migraine headache (ICHD-II criteria for migraine
without aura or migraine with aura). A probable migraine
day was defined as a day with 4 or more continuous hours
of probable migraine headache (ICHD-II for probable
migraine).
Statistical analyses
The psychometric evaluation of the HIT-6 was con-
ducted in a sequential process. First, analyses were con-
ducted to test the comparability of the two study
samples and evaluate the adequacy of analytical ap-
proaches that may be sensitive to distributional charac-
teristics. Specifically, the chi-square test was used to detect
differences in categorical variables while the parallel-group
t-test was used to detect differences in continuous vari-
ables. Next, several analyses were conducted to ensure the
stability of the HIT-6 measurement model. Confirmatory
factor analysis (CFA) was employed in order to ensure
consistency with the HIT-6 measurement model. Multi-group CFA was used to conduct tests of measurement in-
variance across the two clinical trials and longitudinal
measurement invariance. Testing for differential item func-
tioning (DIF) was conducted to establish the cross-cultural
comparability of HIT-6 scores from participants in the
United States, Canada, and four European countries
(Croatia, Germany, Switzerland, and United Kingdom).
Upon the verification of the stability of the HIT-6
measurement model, item-level psychometric indica-
tors were examined, followed by an evaluation of the
instrument’s reliability, construct validity, and ability
to detect change.
Structural validity
The latent structure of the HIT-6 was examined under
CFA using baseline. Consistent with a single dominant
trait measurement model [10,19], our hypothesis was
that the factor loadings of a one-factor model would be
at least moderate in magnitude (>0.50) and similar across
items. Multi-group categorical CFA was then employed to
examine whether the measurement model of the HIT-6
was invariant across the two studies. Invariance testing
was conducted by imposing a series of hierarchical equal-
ity constraints across these two samples. Using the guide-
lines provided by Millsap and Yun-Tein [22], we began by
fitting a model in which all parameters (except the loading
of the first item, which was set equal to 1 for model identi-
fication purposes) were freely estimated across studies
(configural invariance). Invariance testing proceeded by
comparing the chi-square value of this model to a model
where item thresholds were constrained to equality across
studies (scalar invariance). A third model was then fit in
which both item thresholds and loadings (metric invari-
ance) were constrained to equality across groups, and its
chi-square value was compared to that of the scalar invari-
ance model. The last comparison was made between the
metric invariance model and a model that further re-
stricted residual variances to be equal across groups. In-
variance was evaluated by comparing the chi-square
values from nested models where parameters were fixed
across studies [23]. At each step, invariance was verified if
the model with the greater number of constraints was not
significantly different from the initial model. If the full se-
quence of invariance tests was verified, then total meas-
urement invariance across studies was deemed to be
present. CFA was conducted using the robust weighted
least squares estimator as implemented in MPlus (version
5.1) [24]. The CFA model fit was assessed using several in-
dicators: comparative fit index (CFI), Tucker-Lewis Index
(TLI), root mean square error of approximation (RMSEA),
and weighted root mean residual (WRMR). Hu and
Bentler’s [18] guidelines were used to interpret the values
of CFI and TLI (≥.95), RMSEA (<.06), and WRMR (<.90),
indicating good fit.
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investigated by examining measurement invariance across
country- or region-specific groups of patients. The sample
sizes of the four European countries were insufficient to
carry out country-specific analyses of measurement invari-
ance. Hence, our analysis was based on the following
groups: United States, Canada, and pooled European
countries. DIF tests were carried out under the method of
Crane, Gibbons, and Jolley [25]. Under this method, or-
dinal logistic regression models are fit to each item, using
group membership and trait level as the explanatory vari-
ables. To take into account current expert recommenda-
tions [26], two alternative trait estimates were used: (1)
factor scores estimated from the ordinal CFA (configural
model) and (2) HIT-6 sum scores. For each type of trait
estimate, the following sequential process was used to test
for the presence of DIF: first, we tested the presence of
item bias throughout the trait continuum (or uniform
DIF) by examining the change in the trait level coefficient
brought about by removing the group membership term
from the model. Changes to the trait-level coefficient
higher than 10% were indicative of item bias. Results of
simulation studies have shown this latter criterion to be
superior to the 0.05 threshold for statistical significance of
the trait-level coefficient [27]. Second, we tested whether
the relationship between migraine impact and item scores
was dependent on country group (non-uniform DIF). This
test was conducted by evaluating whether the interaction
term between group membership and trait level was sig-
nificant at a confidence level equal to 0.0083 (=0.05/6). In
accordance with the approach of Crane and colleagues
[25], a Bonferroni correction for multiple comparisons
was applied, due to testing for each of the 6 items of
HIT-6. The assumption of proportional odds was thought
to be violated if the P-value for the score test was below
0.05 and the plots of the empirical logits indicated nonpar-
allel lines [28].
Reliability
Indices of reliability reflect the consistency and reprodu-
cibility of scores produced by a particular measurement
procedure. Two distinct methods were used to estimate
reliability: (1) test-retest reliability was evaluated by cor-
relating scores from one administration with scores
from another administration, for participants who
self-reported stable migraine symptoms across admin-
istrations; and (2) internal consistency reliability was
evaluated by examining the equivalence of responses in
a single administration. To evaluate test-retest reliabil-
ity, a “stable” subsample was first identified at Study
Weeks 8 and 12. Participants were considered stable
across these two time points if, at Week 12, they answered
“my migraine symptoms are the same” to the question
“What effect has your current medication(s) had on yourmigraine symptoms in the past 4 weeks?” (item 2 of the
Migraine Treatment Satisfaction Questionnaire). The
intra-class correlation coefficient (ICC) was then evaluated
among the stable subsample in each study and interpreted
using established criteria [29]. Internal consistency reli-
ability of the HIT-6 at baseline and Week 24 was mea-
sured with three indices: Cronbach’s alpha, the average
inter-item correlation [30], and the item-total correlation
after correcting for overlap, i.e., after removing the item
from the total score. Cronbach’s alpha was evaluated
against currently recommended criteria [31]. Item-total
correlations and average inter-item correlations of 0.4 or
higher were deemed indicative of good reliability [32].
Construct validity
The convergent validity of the HIT-6 scores was assessed
in relation to MSQ scores. Correlation coefficients, eval-
uated at baseline and at Week 24, were interpreted as in-
dicative of convergent validity if they were < −0.40. The
negative sign reflects the fact that while higher scores in
the HIT-6 are indicative of greater headache impact,
higher scores on the MSQ are indicative of better
HRQOL.
Construct validity was also examined using the frame-
work of known-groups validity [33]. This approach con-
sists of comparing mean scale scores across groups
known to differ on a clinical criterion measure. In the
present study, groups were based on the following clin-
ical indicators of chronic migraine: 1) number of head-
ache days within a 28-day period and 2) cumulative
hours of headache within a 28-day period. Drawing on
classification criteria previously used in migraine research
[34], participants were classified into one of three head-
ache frequency categories: <10 headache days, 10–14
headache days, or ≥15 headache days. In addition, four
groups were formed based on quartiles of the sample’s
(combined study 1 and study 2) distribution of cumulative
hours of headache: 1) <140 hours, 2) 140 to <280 hours,
3) 280 to <420 hours, and 4) ≥420 hours. These cutoffs
corresponded to an average of approximately <5 hours,
5–10 hours, >10–15 hours, and ≥15 hours of headache
per day, respectively. Because eligibility required study
participants to have a minimum of 15 headache days
in a 28-day period, baseline data were not used in
these analyses. Therefore, known-groups validity ana-
lyses were performed using data from Week 24.
Responsiveness
The responsiveness of the HIT-6 was evaluated against
changes (baseline to Week 24) in number of headache
days and cumulative hours of headache in the pooled
onabotulinumtoxinA arms of both studies. Participants
were categorized according to the direction and magni-
tude of change in these measures. In agreement with
Table 1 Characteristics of study participants at baseline
(N = 1,384)
Characteristics
Study 1 Study 2
(n = 679) (n = 705)
Age (years), mean (SD) 41.7 (10.5) 41.0 (10.6)
Gender, n (% female) 594 (87.5) 602 (85.4)
Race
Caucasian 614 (90.4) 633 (89.8)
Black 30 (4.4) 44 (6.2)
Hispanic 29 (4.3) 17 (2.4)
Asian 3 (0.4) 4 (0.6)
Other 3 (0.4) 7 (1.0)
Migraine Characteristics
Years since frequent migraine onset,
mean (SD)
20.4 (13.0) 18.0 (12.1)
Number of headache days during the
28 day baseline period, mean (SD)
19.9 (3.7) 19.8 (3.6)
Number of migraine days in a 28-day
period, mean (SD)
16.5 (5.8) 16.3 (5.8)
Number of migraine/probable
migraine days in a 28-day period,
mean (SD)
19.1 (4.0) 18.9 (4.0)
Cumulative hours of headache in
a 28-day period, mean (SD)
285.3 (114.3) 291.6 (119.6)
HIT-6a, mean (SD) 65.6 (4.0) 65.3 (4.4)
MSQb
Role function - preventive 55.4 (21.0) 56.7 (21.9)
Role function - restrictive 37.8 (16.8) 39.4 (17.0)
Emotional function 40.3 (24.1) 44.1 (24.8)
aHIT-6 varies between 36 and 78, with higher scores indicating higher
headache impact. Of the 1,384 patients enrolled, 1,376 participants (n = 672
for Study 1 and n = 704 for Study 2) had HIT-6 scores at baseline.
bThe MSQ total and scale score varies between 0 and 100, with higher scores
indicating less impact.
HIT-6 = Headache Impact Test-6; MSQ =Migraine-Specific Questionnaire.
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Headache Society Clinical Trials Subcommittee [8], a
subject was categorized as “much improved” if the 28-
day frequency of headache days decreased by ≥50%; as
“moderately improved” if this decrease was ≥30%
but <50%; and as “not improved” if this decrease
was <30% or if worsening was reported. A similar
categorization scheme was applied to our second criter-
ion measure, cumulative hours of headache. Due to the
small number of study participants reporting worsening
of either frequency of headache days or cumulative
hours of headache, worsening was combined with im-
provement that was not deemed significant (<30%).
HIT-6 change scores were found to be approximately
normally distributed supporting the use of analysis of
variance (ANOVA) models to evaluate whether group
differences in mean HIT-6 change score were statistically
significant. The standardized response mean (SRM),
which is a measure of effect size calculated as the ratio
of the mean HIT-6 change score to its standard devi-
ation, was evaluated to help interpret the magnitude of




Table 1 presents the main demographic and clinical
characteristics separately for each study sample. Of
1,384 patients enrolled in the two studies, 1,376 had
HIT-6 scores at baseline. Overall, study participants
were primarily female and Caucasian, and had an aver-
age age of approximately 41 years. Based on patients’
baseline assessment, the average number of migraine
days in a 28-day period was approximately 16 (19 when
probable migraine days were included), the average
number of headache days was approximately 20, and the
average cumulative hours of headache in the 28 day
period was approximately 288.
Baseline scores on the HIT-6 and MSQ were nearly
identical across the two studies. At baseline, the aver-
age HIT-6 score was approximately 65 (65.6 and 65.3
for studies 1 and 2, respectively), reflecting a severe
level of headache impact [19]. Scores on the MSQ
were also reflective of severe impact. The order of in-
creasing severity was constant across the two studies,
with migraine-attributable interruptions in daily activ-
ities (role-preventive dimension) reflecting the lowest
impact and limitations due to migraine (role-restrictive
dimension) being the most severely affected of the
three MSQ dimensions.
The demographic and migraine characteristics of patients
were nearly identical across studies, as were the distribu-
tions of scores for each HIT-6 item. At baseline, about 30%
of patients reported that they frequently wished they couldlie down. Approximately the same proportion also stated
that they frequently felt irritated because of their headaches.
These two items stood out as those occurring with greatest
frequency. For each of the remaining four items (pain, daily
activities interference, too tired to do work/daily activities,
and ability to concentrate), between 5% and 8% of patients
said it occurred frequently. Nevertheless, about 62% of the
overall sample said headaches very often limited their abil-
ity to concentrate.
Structural validity
The standardized loadings obtained under the configural
model (Table 2) indicated that, across the two studies,
all HIT-6 items were similarly strongly correlated with
headache impact. Restricting model parameters to equal-
ity across the two studies did not result in a significant
deterioration of model fit, as measured by the chi-square
test for nested models (Table 3). Indeed, the values
Table 2 Standardized factor loadings from confirmatory
factor analysis*
HIT-6 item
Study 1 Study 2









Ab Pain Severe When
Headache
0.652 (0.032) 0.740 (0.025)
B Limit Ability to Do
Daily Acts
0.770 (0.023) 0.797 (0.020)
C Wish Could Lie Down 0.536 (0.032) 0.658 (0.028)
D Too Tired to Do Work
or Daily Acts
0.785 (0.022) 0.796 (0.021)
E Feel Fed Up/Irritated
Because of Headache
0.533 (0.033) 0.554 (0.031)
F Limit Ability to
Concentrate
0.751 (0.027) 0.744 (0.024)
aOnly includes participants with complete item level HIT-6 data.
bFactor loading fixed to one for identification purposes.
RMSEA = 0.086; WRMR = 1.263; CFI/TLI = 0.976/0.978.
CFI = comparative fit index; RMSEA = root mean square error of approximation;
TLI = Tucker-Lewis Index; WRMR = weighted root mean square residual.
*Configural Invariance Model at Baseline.
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a slightly better fit is obtained under total measurement
invariance across studies. These results provide evidence
that the measurement model of the HIT-6 remained
stable across two independent samples of chronic mi-
graine patients. Tests of measurement invariance across
country groups (Table 4) showed no evidence of uniform
or non-uniform DIF, as indicated by the small changes
in the value of the trait level coefficient after removal
and likelihood-ratio tests comparing the models with
and without the trait-level group membership inter-
action, respectively. In addition, results (not shown)
using the HIT-6 sum score as the trait level variable (in-
stead of CFA factor scores) resulted in identical conclu-
sions. Inspection of the score test in conjunction with
plots of the empirical logits suggested that the propor-
tional odds assumption was not met by the item “In the
past 4 weeks, how often have you felt fed up or irritated
because of your headaches?” Nevertheless, the degree ofTable 3 Tests of measurement invariance using multi-group c
Model fit
Parameter constraints TLI CFI R
Measurement Invariance Across Studies
None - Configural Model 0.979 0.978 0
Thresholds 0.990 0.980 0
Thresholds and loadings 0.992 0.982 0
Thresholds, loadings, and residual variances 0.993 0.982 0
Values under the column heading “Model Comparison” refer to the comparison of
CFI = comparative fit index; ΔCFI = change in CFI; DF = degrees of freedom; RMSEA
TLI = Tucker-Lewis Index.non-parallelism shown in the plot was small (results not
shown).
Reliability
Study-specific estimates of the ICC, used to measure test-
retest reliability, were generally indicative of good reliability
(Table 5). The ICC was 0.80 (95% confidence interval
[CI] = [0.75, 0.83]) for study 1 and 0.76 (95% CI = [0.72,
0.80]) for study 2 (Table 5). Cronbach’s alpha was consist-
ently above the recommended threshold for acceptable reli-
ability (0.70) and close to values indicating good to
excellent reliability (>0.80). The relative contribution of
each item to the scale’s internal consistency was assessed by
evaluating alpha-removed statistics (results not shown).
The magnitude of change in Cronbach’s alpha was nearly
uniform across items, and in no instances did removal of
an item from the scale result in an increase in the value of
Cronbach’s alpha. Item-total correlations of 0.40 or higher
were observed for all items across time and studies, sup-
porting the validity of each item to the total scale. At base-
line, the average inter-item correlation was 0.45 for study 1
and 0.53 for study 2. Both values are higher than the rec-
ommended threshold of 0.40 [32]. Overall, using recom-
mended interpretation guidelines, measures of reliability
were homogeneously supportive of the hypothesis of con-
sistent and reproducible HIT-6 scores among the two sam-
ples of chronic migraine patients.
Construct validity
Correlations between HIT-6 total scores and scale scores
of the MSQ (absolute values) were above the recom-
mended threshold of 0.40 for convergent validity [32]
across studies and time points, ranging between −0.86
and −0.59 (Table 6), suggesting good convergent validity.
Known-groups validity analyses were supportive of the
validity of the HIT-6 scores with respect to clinical criter-
ion measures (Table 7). For study 1, at Week 24, mean
HIT-6 scores were significantly different across levels of
headache frequency (P-value <0.001), with values equal to
58.4, 62.9 and 65.0, for individuals experiencing <10,
10–14, and ≥15 days of headache, respectively. Very similaronfirmatory factor analysis
Model comparison
MSEA ΔCFI ΔRMSEA
Chi-square for nested model
comparison
.086 — — —
.059 0.002 −0.027 22.754 (DF = 15); (P = 0.0895)
.052 0.002 −0.007 3.579 (DF = 4); (P = 0.4659)
.050 0.000 −0.002 9.655 (DF = 6); (P = 0.1399)
the model in the corresponding row and the model in the preceding row.
= root mean square error of approximation; ΔRMSEA = change in RMSEA;
Table 4 Tests of measurement invariance across country groups
HIT-6 item N
Percent change in
the value of the
coefficienta
Significance testing for interaction between
country and trait level*
Wald chi-square DF P-value
A Pain Severe When Headache 1,375 0.2 5.187 2 0.0747
B Limit Ability to Do Daily Acts 1,376 2.8 6.402 2 0.0407
C Wish Could Lie Down 1,376 2.2 1.847 2 0.3971
D Too Tired to Do Work or Daily Acts 1,376 0.1 1.241 2 0.5377
E Feel Fed Up/Irritated Because of
Headache
1,375 7.8 2.243 2 0.3258
F Limit Ability to Concentrate 1,376 1.4 2.362 2 0.3070
*P-values <0.0083 (=0.05/6) indicate non-uniform DIF.
aPercent change in the trait level coefficient after removing the country group indicators from the model; values ≥10% indicate uniform DIF.
DF = degrees of freedom; DIF = differential item functioning.
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scores were higher in groups indicating greater impact of
migraine, as represented by quartiles of cumulative hours
of headache. These results were consistent across the two
studies.
Responsiveness
Across both studies, the mean HIT-6 change score was
significantly greater for groups of patients representing
greater degree of improvement in frequency of headache
days and cumulative hours of headache (Table 8). On
average, patients experiencing at least a 50% improve-
ment in the number of headache days reported a nearly
7-point decrease in HIT-6 score, far exceeding the estab-
lished MID of a 2.3-point decrease [12]. Patients who
experienced moderate improvement reported an average
decrease of 3.3 and 2.9 points, for studies 1 and 2, re-
spectively, while the mean decrease in HIT-6 scores for
patients experiencing less than a 30% reduction in the
number of headache days was −0.7, for both studies. Dif-
ferences in mean HIT-6 change scores were similar
across groups of patients representing greater degree of
improvement in cumulative hours of headache. Using
the guidelines of Cohen [35], these results indicate large
(0.8), medium (0.5), and low (0.2) effect sizes for highest
(≥50%), moderate (≥30% to <50%), and lowest (<30%) cat-
egories of improvement. The gradient of change across







1 362 0.80 [0.75, 0.83] 0.75
2 349 0.76 [0.72, 0.80] 0.79
aParticipants who, at Week 12, answered “my migraine symptoms are the same” to
migraine symptoms in the past 4 weeks?”.
bICC = intra-class correlation coefficient; estimated for measurements made at Week
cStudy 1: N baseline = 672; N week 24 = 580; study 2: N baseline = 702; N week 24 = 637.
HIT-6 = Headache Impact Test-6.suggests that the HIT-6 appropriately captures changes in
migraine frequency in chronic migraine patients.
Discussion
The findings of the current study support the stability of
the HIT-6 measurement model, the tool’s construct val-
idity, and its ability to detect change in clinical indica-
tors of headache in two independent samples of chronic
migraine patients undergoing treatment. Using recom-
mended guidelines for interpretation of change in clin-
ical indicators of headache [8], we found that the HIT-6
captured different levels of change exceptionally well, as
indicated by measures of effect size. Indeed, the magni-
tude and direction of mean HIT-6 change scores were
fully in line with the percentage improvement in head-
ache frequency reported by patients, with strong, moder-
ate, and low effects sizes for the highest (>50%), middle
(30% to 50%), and lowest (<30%) categories of improve-
ment, respectively. Improvement of at least 50% in head-
ache day frequency was accompanied by an average
increase in HIT-6 scores of approximately 7 points,
which substantially exceeds previous estimates of pa-
tients’ perceptions of meaningful change [12]. Our find-
ings concerning the reliability and construct validity of
the HIT-6 also demonstrate that the instrument has ex-
cellent properties in this respect. Previous studies
[10,11] reported internal consistency estimates for the
HIT-6 that ranged between 0.89 and 0.90, a result thatphac Average inter-item polychoric correlationc
Week 24 Baseline Week 24
0.92 0.45 0.73
0.91 0.53 0.72
the question “What effect has your current medication(s) had on your
s 8 and 12.
Table 6 Convergent validity: correlations between HIT-6 and MSQ scores
Time point Item/Scale
Study 1 Study 2
Correlationa N Correlationa N
Baseline Total −0.77 (671) −0.78 (703)
Emotional function −0.62 (671) −0.59 (703)
Role function - preventive −0.67 (672) −0.66 (704)
Role function - restrictive −0.75 (672) −0.78 (704)
Week 24 Total −0.85 (576) −0.83 (637)
Emotional function −0.78 (576) −0.74 (637)
Role function - preventive −0.74 (579) −0.74 (637)
Role function - restrictive −0.86 (580) −0.84 (637)
aPearson product moment correlations.
HIT-6 = Headache Impact Test-6; MSQ =Migraine-Specific Questionnaire.
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found similar agreement between our estimates of test-
retest scale reliability (the ICC was equal to 0.80 for
study 1 and 0.76 for study 2) and those reported in the
HIT-6 validation study [10]. The convergent validity of
the HIT-6 was also supported by the finding of strong
correlations (−0.9 to −0.6) with the MSQ. Construct val-
idity was also evaluated using data from Week 24 in a
known-groups framework. The results of these analyses
showed that HIT-6 scores can be used to discriminate
between patients with low-frequency episodic migraine
(<10 days), high-frequency episodic migraine (10–14
days), and chronic migraine (≥15 days), a result that re-
inforces the findings of a previous study [15].
Some limitations should be taken into account in the in-
terpretation of the study’s findings. First, the patient sample
was taken from two clinical trials, therefore generalizability
to the general population of chronic migraine patients may
be limited. Second, the sample is representative of those
migraine patients receiving onabotulinumtoxinA as
prophylactic treatment and may not be generalizableTable 7 Known-groups validity: HIT-6 scores at week 24 in re
Number of headache days
<10 Days 10–14 Days ≥15 D
Study Mean SD N Mean SD N Mean
1 58.4 (8.18) 257 62.9 (5.48) 154 65.0
2 58.2 (8.21) 288 63.3 (6.33) 171 64.6
Cumulative Hours of Headache
Quartile 1: <140 hours Quartile 2: 140 to <280 hours Quart
Study Mean SD N Mean SD N Mean
1 59.1 (7.74) 313 63.6 (5.78) 186 65.5
2 59.2 (8.08) 357 63.5 (5.80) 199 64.8
*P-value <0.001.
aF-Statistics and P-values for between-category comparisons are from analysis of va
in the clinical criterion measure (i.e., headache days or cumulative hours), where the ty
bF-Statistics and P-values for between-category comparisons are from ANOVA. The
criterion measure (i.e., headache days or cumulative hours) and medication-overuse
HIT-6 = Headache Impact Test-6; SD = standard deviation.to other migraine treatments. Nevertheless, CFA re-
sults were similar to those of analyses carried out in a
sample of patients seen in a headache-specialty prac-
tice [11], as were other psychometric properties previ-
ously estimated among a general population of headache
sufferers [10] and more recently in both episodic and
chronic migraine patients [15]. Finally, although we found
no evidence of item bias across the country groups exam-
ined, our sample did not allow for single country compari-
sons. Further, the number of observations in some groups
may have limited the ability to detect mild or moderate
DIF in the HIT-6 items. Although it is known that the es-
timation of ordinal logistic regression parameters is af-
fected by the size of the sample, a recent study [36]
examining the effect of sample size on the power to detect
DIF indicated that when the group size is equal to 100
and the number of items is 6, ordinal logistic regression
can detect strong DIF with high power (>90%), although
power to detect moderate DIF is considerably lower
(<60%). In the current study, two of the language groups
had sample sizes of approximately 100, thus suggestinglation to clinical criterion measures
ays
SD N Fa Fb
(5.70) 268 125.02* 125.28*
(5.17) 246 120.71* 114.87*
ile 3: 280 to <420 hours Quartile 4: ≥420 hours
SD N Mean SD N Fa Fb
(5.27) 106 65.9 (6.27) 74 105.97* 110.12*
(5.15) 90 66.0 (5.49) 59 89.50* 88.38*
riance (ANOVA). The main effect in the ANOVA was ranked category of decrease
pe III sum of squares was used.
main effects in the ANOVA included ranked category of decrease in the clinical
strata, where the type III sum of squares was used.
Table 8 Responsiveness: change in HIT-6 scores in relation
to changes in clinical criterion measures
Decrease from baseline in headache days at week 24
Mean
change
in HIT-6 SD n SRM F-valuea F-valueb
Study 1
≥50% −6.9 7.63 255 −0.90
≥30% to <50% −3.3 5.18 141 −0.64
<30% −0.7 4.23 283 −0.17 148.81* 148.33*
Study 2
≥50% −6.9 8.07 291 −0.86
≥30% to <50% −2.9 5.60 131 −0.52
<30% −0.7 4.01 283 −0.18 140.01* 139.62*
Decrease from Baseline in Cumulative Hours of Headache
Occurring on Headache Days at Week 24
Mean
Change
in HIT-6 SD n SRM F-valuea F-valueb
Study 1
≥50% −6.9 7.50 269 −0.92
≥30% to <50% −2.6 5.24 115 −0.50
<30% −0.9 4.30 295 −0.21 142.06* 143.15*
Study 2
≥50% −6.5 8.05 319 −0.81
≥30% to <50% −2.2 4.64 109 −0.47
<30% −0.9 4.41 277 −0.20 112.72* 112.07*
*P-value <0.001.
aF-Statistics and P-values for between-category comparisons are from analysis
of variance (ANOVA). The main effect in the ANOVA was ranked category of
decrease in the clinical criterion measure (i.e., headache days or cumulative
hours), where the type III sum of squares was used.
bF-Statistics and P-values for between-category comparisons are from analysis
of variance (ANOVA). The main effects in the ANOVA included ranked category
of decrease in the clinical criterion measure (i.e., headache days or cumulative
hours) and medication-overuse strata, where the type III sum of squares
was used.
HIT-6 = Headache Impact Test-6; SD = standard deviation; SRM = standardized
response mean.
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among these groups. In addition, the statistical signifi-
cance tests indicated that the proportional odds assump-
tion was not met by one of the six items of the HIT-6. As
extensively documented [37,38], the score test is known to
result in small P-values, even when the departure from
the proportional odds assumption is not significant from a
practical perspective. Although this finding affected a sin-
gle item of the HIT-6 and the degree to which the as-
sumption was violated appeared to be small upon visual
inspection, studies with larger sample sizes across different
countries are warranted to verify the absence of cross-
cultural DIF for the HIT-6. Importantly, our findings
agree with a previous study in which the psychometricproperties of the HIT-6 were found to be similar across
11 languages [39].
Conclusions
The evidence presented in the current study and its
consistency with results from prior studies suggest that
the HIT-6 has excellent properties to measure the im-
pact of headache across a wide spectrum of headache
frequency, including chronic migraine, and in different
clinical and research settings.
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